Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Pred Forte
2. Prednisolone 21-acetate
3. Scherisolone-kristall Suspension
1. 52-21-1
2. Prednisolone 21-acetate
3. Omnipred
4. Econopred
5. Pricortin
6. Cormalone
7. Cortipred
8. Deltilen
9. Durapred
10. Predicort
11. Prednidoren
12. Supercortyl
13. Prenema
14. Meticortelone Acetate
15. Prednelan-n
16. Delcort-e
17. Pred Mild
18. Pred Forte
19. Flo-pred
20. Prediacortine
21. Nisolone
22. Prednisolone-21-acetate
23. Predalone 50
24. Predonine Injection
25. Nsc-10966
26. Mls000028512
27. Chebi:8380
28. [2-[(8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] Acetate
29. Prednisolone (21-acetate)
30. Smr000058326
31. Econopred Plus
32. 8b2807733d
33. Nsc 10966
34. Dsstox_cid_3502
35. Dsstox_rid_77056
36. Dsstox_gsid_23502
37. Prednisoloneacetate
38. 21-acetoxy-1,4-pregnadiene-11beta,17alpha-diol-3,20-dione
39. Pred-forte
40. Cetapred Ointment
41. Pred-g Liquifilm
42. Vasocidin Ointment
43. Cas-52-21-1
44. Blephamide Liquifilm
45. Einecs 200-134-1
46. Prednisolone Acetate (omnipred)
47. Brn 3111798
48. Prednisolone Acetate [usp:jan]
49. Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11,17-dihydroxy-, (11.beta.)-
50. Econopred (tn)
51. Prednisoloni Acetas
52. Unii-8b2807733d
53. Ncgc00094765-01
54. Prednisolone-acetate
55. Pred Forte (tn)
56. Component Of Metimyd
57. Mfcd00037710
58. Sterane Im And Ia
59. Blephamide S.o.p.
60. Component Of Composone
61. Pred Forte Tm 1%
62. Opera_id_332
63. Pred-g S.o.p.
64. 11beta,17,21-trihydroxypregna-1,4-diene-3,20-dione 21-acetate
65. Schembl7999
66. Chembl1152
67. Component Of Isopto Cetapred
68. 4-08-00-03468 (beilstein Handbook Reference)
69. Mls001148097
70. Mls002207146
71. Mls002548870
72. Component Of Neo-delta-cortef
73. Dtxsid3023502
74. Hms2234f18
75. Hms3259o07
76. Prednisolone Acetate [jan]
77. Prednisolone 21-acetate, >=97%
78. Prednisone Impurity L [ep]
79. 2-((8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3h-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl Acetate
80. Bcp18958
81. Hy-b1214
82. Nsc10966
83. Zinc3875348
84. Prednisolone Acetate [vandf]
85. Tox21_111328
86. Prednisolone Acetate [mart.]
87. Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-, 21-acetate
88. S2570
89. Prednisolone Acetate [usp-rs]
90. Prednisolone Acetate [who-dd]
91. Prednisolone Acetate [who-ip]
92. Akos007930677
93. Akos015960469
94. Prednisolone 21-acetate [mi]
95. Pregna-1,4-diene-3,20-dione, 11-beta,17,21-trihydroxy-, 21-acetate
96. Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11,17-dihydroxy-, (11beta)-
97. Tox21_111328_1
98. Ac-2176
99. Ccg-268673
100. Cs-4642
101. Db15566
102. Nc00470
103. Prednisolone Acetate (jp17/usp/inn)
104. Ncgc00021925-03
105. Ncgc00021925-05
106. Prednisolone Acetate [green Book]
107. 2-((1s,10s,11s,15s,17s,2r,14r)-14,17-dihydroxy-2,15-dimethyl-5-oxotetracyclo[8 .7.0.0<2,7>.0<11,15>]heptadeca-3,6-dien-14-yl)-2-oxoethyl Acetate
108. As-11673
109. Prednisolone Acetate [orange Book]
110. Prednisolone Acetate [ep Monograph]
111. Prednisolone Acetate [usp Impurity]
112. Prednisoloni Acetas [who-ip Latin]
113. Prednisolone Acetate [usp Monograph]
114. Prednisolone Acetate For Peak Identification
115. Metimyd Component Prednisolone Acetate
116. P1283
117. Pred-g Component Prednisolone Acetate
118. Prednisolone Impurity C [ep Impurity]
119. Cetapred Component Prednisolone Acetate
120. Sulphrin Component Prednisolone Acetate
121. Blephamide Component Prednisolone Acetate
122. C08180
123. D00980
124. Poly-pred Component Prednisolone Acetate
125. Predamide Component Prednisolone Acetate
126. Prednisolone Acetate 100 Microg/ml In Methanol
127. Prednisolone Acetate Component Of Pred-g
128. Ab00443788-11
129. Ab00443788_13
130. Prednisolone Acetate 1000 Microg/ml In Methanol
131. Prednisolone Acetate Component Of Cetapred
132. Prednisolone Acetate Component Of Metimyd
133. Prednisolone Acetate Component Of Sulphrin
134. Predsulfair Component Prednisolone Acetate
135. 037p710
136. A828982
137. Prednisolone Acetate Component Of Blephamide
138. Prednisolone Acetate Component Of Poly-pred
139. Prednisolone Acetate Component Of Predamide
140. Prednisolone Acetate Component Of Predsulfair
141. Q-201614
142. Hydrocortisone Acetate Impurity C [ep Impurity]
143. Isopto Cetapred Component Prednisolone Acetate
144. Neo-delta-cortef Component Prednisolone Acetate
145. Q27108063
146. Blephamide S.o.p. Component Prednisolone Acetate
147. Prednisolone Acetate Component Of Isopto Cetapred
148. Prednisolone Acetate Component Of Neo-delta-cortef
149. Methylprednisolone Acetate Impurity E [ep Impurity]
150. Prednisolone 21-acetate, Vetranal(tm), Analytical Standard
151. Prednisolone Acetate Component Of Blephamide S.o.p.
152. 11b,17,21-trihydroxypregna-1,4-diene-3,20-dione 21-acetate
153. Pregna-1,20-dione, 11.beta.,17,21-trihydroxy-, 21-acetate
154. Prednisolone Acetate, British Pharmacopoeia (bp) Reference Standard
155. Prednisolone Acetate, European Pharmacopoeia (ep) Reference Standard
156. (11beta)-11,17-dihydroxy-3,20-dioxopregna-1,4-dien-21-yl Acetate
157. 11.beta.,17,21-trihydroxypregna-1,4-diene-3,20-dione 21-acetate
158. 11.beta.,17-dihydroxy-3,20-dioxopregna-1,4-dien-21-yl Acetate
159. Prednisolone Acetate, United States Pharmacopeia (usp) Reference Standard
160. Pregna-1,20-dione, 21-(acetyloxy)-11,17-dihydroxy-, (11.beta.)-
161. Prednisolone Acetate For Peak Identification, European Pharmacopoeia (ep) Reference Standard
162. Prednisolone Acetate, Pharmaceutical Secondary Standard; Certified Reference Material
163. [2-[(8s,9s,10r,11s,13s,14s,17r)-10,13-dimethyl-11,17-bis(oxidanyl)-3-oxidanylidene-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-yl]-2-oxidanylidene-ethyl] Ethanoate
164. Acetic Acid [2-[(8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] Ester
| Molecular Weight | 402.5 g/mol |
|---|---|
| Molecular Formula | C23H30O6 |
| XLogP3 | 2.4 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 4 |
| Exact Mass | 402.20423867 g/mol |
| Monoisotopic Mass | 402.20423867 g/mol |
| Topological Polar Surface Area | 101 Ų |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 827 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 7 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 10 | |
|---|---|
| Drug Name | Blephamide s.o.p. |
| PubMed Health | Prednisolone |
| Drug Classes | Endocrine-Metabolic Agent, Immune Suppressant, Ophthalmologic Agent |
| Drug Label | Flo-Pred (prednisolone acetate oral suspension) contains prednisolone which is the acetate ester of the glucocorticoid prednisolone. Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from... |
| Active Ingredient | sulfacetamide sodium; Prednisolone acetate |
| Dosage Form | Ointment |
| Route | Ophthalmic |
| Strength | 0.2%; 10% |
| Market Status | Prescription |
| Company | Allergan |
| 2 of 10 | |
|---|---|
| Drug Name | Flo-pred |
| PubMed Health | Prednisolone |
| Drug Classes | Endocrine-Metabolic Agent, Immune Suppressant, Ophthalmologic Agent |
| Drug Label | OMNIPRED (prednisolone acetate ophthalmic suspension) is an adrenocortical steroid product prepared as sterile ophthalmic suspension. The active ingredient is represented by the chemical structure:Established name: Prednisolone AcetateChemical name... |
| Active Ingredient | Prednisolone acetate |
| Dosage Form | Suspension |
| Route | Oral |
| Strength | eq 15mg base/5ml |
| Market Status | Prescription |
| Company | Taro |
| 3 of 10 | |
|---|---|
| Drug Name | Omnipred |
| PubMed Health | Prednisolone (Into the eye) |
| Drug Classes | Ophthalmologic Agent |
| Drug Label | PRED FORTE (prednisolone acetate ophthalmic suspension, USP) 1% is a topical anti-inflammatory agent for ophthalmic use.... |
| Active Ingredient | Prednisolone acetate |
| Dosage Form | Suspension/drops |
| Route | Ophthalmic |
| Strength | 1% |
| Market Status | Prescription |
| Company | Alcon |
| 4 of 10 | |
|---|---|
| Drug Name | Pred forte |
| Drug Label | PRED MILD (prednisolone acetate ophthalmic suspension, USP) 0.12% is a topical anti-inflammatory agent for ophthalmic use. Structural Formula:... |
| Active Ingredient | Prednisolone acetate |
| Dosage Form | Suspension/drops |
| Route | Ophthalmic |
| Strength | 1% |
| Market Status | Prescription |
| Company | Allergan |
| 5 of 10 | |
|---|---|
| Drug Name | Pred mild |
| Active Ingredient | Prednisolone acetate |
| Dosage Form | Suspension/drops |
| Route | Ophthalmic |
| Strength | 0.12% |
| Market Status | Prescription |
| Company | Allergan |
| 6 of 10 | |
|---|---|
| Drug Name | Blephamide s.o.p. |
| PubMed Health | Prednisolone |
| Drug Classes | Endocrine-Metabolic Agent, Immune Suppressant, Ophthalmologic Agent |
| Drug Label | Flo-Pred (prednisolone acetate oral suspension) contains prednisolone which is the acetate ester of the glucocorticoid prednisolone. Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from... |
| Active Ingredient | sulfacetamide sodium; Prednisolone acetate |
| Dosage Form | Ointment |
| Route | Ophthalmic |
| Strength | 0.2%; 10% |
| Market Status | Prescription |
| Company | Allergan |
| 7 of 10 | |
|---|---|
| Drug Name | Flo-pred |
| PubMed Health | Prednisolone |
| Drug Classes | Endocrine-Metabolic Agent, Immune Suppressant, Ophthalmologic Agent |
| Drug Label | OMNIPRED (prednisolone acetate ophthalmic suspension) is an adrenocortical steroid product prepared as sterile ophthalmic suspension. The active ingredient is represented by the chemical structure:Established name: Prednisolone AcetateChemical name... |
| Active Ingredient | Prednisolone acetate |
| Dosage Form | Suspension |
| Route | Oral |
| Strength | eq 15mg base/5ml |
| Market Status | Prescription |
| Company | Taro |
| 8 of 10 | |
|---|---|
| Drug Name | Omnipred |
| PubMed Health | Prednisolone (Into the eye) |
| Drug Classes | Ophthalmologic Agent |
| Drug Label | PRED FORTE (prednisolone acetate ophthalmic suspension, USP) 1% is a topical anti-inflammatory agent for ophthalmic use.... |
| Active Ingredient | Prednisolone acetate |
| Dosage Form | Suspension/drops |
| Route | Ophthalmic |
| Strength | 1% |
| Market Status | Prescription |
| Company | Alcon |
| 9 of 10 | |
|---|---|
| Drug Name | Pred forte |
| Drug Label | PRED MILD (prednisolone acetate ophthalmic suspension, USP) 0.12% is a topical anti-inflammatory agent for ophthalmic use. Structural Formula:... |
| Active Ingredient | Prednisolone acetate |
| Dosage Form | Suspension/drops |
| Route | Ophthalmic |
| Strength | 1% |
| Market Status | Prescription |
| Company | Allergan |
| 10 of 10 | |
|---|---|
| Drug Name | Pred mild |
| Active Ingredient | Prednisolone acetate |
| Dosage Form | Suspension/drops |
| Route | Ophthalmic |
| Strength | 0.12% |
| Market Status | Prescription |
| Company | Allergan |
Prednisolone acetate is indicated as an anti-inflammatory or immunosuppressive agent for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, or infectious conditions. Prednisolone acetate is also indicated in organ transplant patients, as well as endocrine or neoplastic conditions.
Corticosteroids bind to the glucocorticoid receptor, inhibiting pro-inflammatory signals, and promoting anti-inflammatory signals. Prednisolone acetate has a short duration of action as the half life is 2-3 hours. Corticosteroids have a wide therapeutic window as patients make require doses that are multiples of what the body naturally produces. Patients taking corticosteroids should be counselled regarding the risk of hypothalamic-pituitary-adrenal axis suppression and increased susceptibility to infections.
Anti-Inflammatory Agents
Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)
Absorption
Prednisolone acetate oral suspension given at a dose equivalent to 15mg prednisolone has a Cmax of 321.1ng/hr, a Tmaxof 1-2 hours, and an AUC of 1999.4ng\*hr/mL. The absorption pharmacokinetics of prednisolone acetate are not significantly different from a comparable dose of prednisolone.
Route of Elimination
Prednisolone acetate is predominantly excreted in the urine.
Volume of Distribution
The volume of distribution of the active metabolite, prednisolone, is 0.22/0.7L/kg.
Clearance
Data regarding the clearance of prednisolone acetate is not readily available.
Prednisolone acetate undergoes ester hydrolysis to [prednisolone]. After this step, the drug undergoes the normal metabolism of prednisolone. Prednisolone can be reversibly metabolized to [prednisone] which is then metabolized to 17,21-dihydroxy-pregnan-1,4,6-trien-3,11,30-trione (M-XVII), 20-dihydro-prednisone (M-V), 6hydroxy-prednisone (M-XII), 6-hydroxy-prednisone (M-XIII), or 20-dihydro-prednisone (M-IV). 20-dihydro-prednisone is metabolized to 17,20,21-trihydroxy-5-pregn-1-en-3,11-dione(M-XVIII). Prednisolone is metabolized to 6-prednisolone (M-XI), 20-dihydro-prednisolone (M-III), 20-dihydro-prednisolone (M-II), 6hydroxy-prednisolone (M-VII), or 6hydroxy-prednisolone(M-VI). 6hydroxy-prednisolone is metabolized to 6,11,17,20,21-pentahydroxypregnan-1,4-diene-3-one (M-X). 6hydroxy-prednisolone is metabolized to 6,11,17,20,21-pentahydroxypregnan-1,4-diene-3-one (M-VIII), 6,11,17,20,21-pentahydroxypregnan-1,4-diene-3-one (M-IX), and 6,11,17,21-tetrahydroxy-5-pregn-1-en-3,20-dione (M-XIV). MVIII is metabolized to 6,11,17,20,21-pentahydroxy-5-pregn-1-en-3-one (M-XV) and then to MXIV, while MIX is metabolized to 6,11,17,20,21-pentahydroxy-5-pregn-1-en-3-one (M-XVI) and then to MXIV. These metabolites and their glucuronide conjugates are excreted predominantly in the urine.
Oral prednisolone acetate has a plasma half life of 2-3 hours.
The short term effects of corticosteroids are decreased vasodilation and permeability of capillaries, as well as decreased leukocyte migration to sites of inflammation. Corticosteroids binding to the glucocorticoid receptor mediates changes in gene expression that lead to multiple downstream effects over hours to days. Glucocorticoids inhibit neutrophil apoptosis and demargination; they inhibit phospholipase A2, which decreases the formation of arachidonic acid derivatives; they inhibit NF-Kappa B and other inflammatory transcription factors; they promote anti-inflammatory genes like interleukin-10. Lower doses of corticosteroids provide an anti-inflammatory effect, while higher doses are immunosuppressive. High doses of glucocorticoids for an extended period bind to the mineralocorticoid receptor, raising sodium levels and decreasing potassium levels.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
Cyclosporine is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Conjunctivitis, Allergic.
Lead Product(s): Cyclosporine,Prednisolone Acetate
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 10, 2010
Lead Product(s) : Cyclosporine,Prednisolone Acetate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cyclosporine is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Conjunctivitis, Allergic.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
May 10, 2010
Details:
Mirvetuximab Soravtansine is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Ovarian Neoplasms.
Lead Product(s): Mirvetuximab Soravtansine,Macrogol,Prednisolone Acetate
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody-drug Conjugate
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 15, 2024
Lead Product(s) : Mirvetuximab Soravtansine,Macrogol,Prednisolone Acetate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Mirvetuximab Soravtansine is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Ovarian Neoplasms.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
April 15, 2024
Details:
Pred Forte-Generic (prednisolone acetate) is a sterile, topical antiinflammatory agent and is indicated for treating steroid-responsive ocular inflammation.
Lead Product(s): Prednisolone Acetate,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Pred Forte-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 12, 2025
Lead Product(s) : Prednisolone Acetate,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
Details : Pred Forte-Generic (prednisolone acetate) is a sterile, topical antiinflammatory agent and is indicated for treating steroid-responsive ocular inflammation.
Product Name : Pred Forte-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 12, 2025
Details:
Pred Forte-Generic (prednisolone acetate) is indicated for the treatment of steroid responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.
Lead Product(s): Prednisolone Acetate,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Pred Forte-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 15, 2024
Lead Product(s) : Prednisolone Acetate,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Launches First Generic of Pred Forte in the US
Details : Pred Forte-Generic (prednisolone acetate) is indicated for the treatment of steroid responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.
Product Name : Pred Forte-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 15, 2024
Details:
Pred Forte-Generic (prednisolone acetate) is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.
Lead Product(s): Prednisolone Acetate,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Pred Forte-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 06, 2024
Lead Product(s) : Prednisolone Acetate,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Receives USFDA Approval for Prednisolone Acetate Ophthalmic Suspension USP
Details : Pred Forte-Generic (prednisolone acetate) is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.
Product Name : Pred Forte-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 06, 2024
Details:
Dexamethasone is a Steroid drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Glaucoma.
Lead Product(s): Dexamethasone,Prednisolone Acetate
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Steroid
Sponsor: Ocular Therapeutix
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 24, 2020
Lead Product(s) : Dexamethasone,Prednisolone Acetate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Ocular Therapeutix
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dexamethasone is a Steroid drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Glaucoma.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
September 24, 2020
Details:
Dexamethasone is a Steroid drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cataract.
Lead Product(s): Dexamethasone,Prednisolone Acetate
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Steroid
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 21, 2020
Lead Product(s) : Dexamethasone,Prednisolone Acetate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dexamethasone is a Steroid drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cataract.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
July 21, 2020
Details:
Dexamethasone is a Steroid drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cataract.
Lead Product(s): Dexamethasone,Prednisolone Acetate
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Steroid
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 18, 2020
Lead Product(s) : Dexamethasone,Prednisolone Acetate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1%
Details : Dexamethasone is a Steroid drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cataract.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
February 18, 2020
Details:
Prednisolone Acetate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cataract.
Lead Product(s): Prednisolone Acetate,Gatifloxacin,Bromfenac
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Science in Vision | Imprimis Pharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 06, 2018
Lead Product(s) : Prednisolone Acetate,Gatifloxacin,Bromfenac
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Science in Vision | Imprimis Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Prophylactic Treatment: Lessdropsâ„¢ vs Standard Drops Regimen
Details : Prednisolone Acetate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cataract.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 06, 2018
Details:
Triamcinolone Acetonide is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cataract.
Lead Product(s): Triamcinolone Acetonide,Moxifloxacin,Vancomycin Hydrochloride,Nepafenac,Moxifloxacin Hydrochloride,Prednisolone Acetate
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Science in Vision
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 04, 2015
Lead Product(s) : Triamcinolone Acetonide, Moxifloxacin, Vancomycin Hydrochloride, Nepafenac, Moxifloxacin Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Science in Vision
Deal Size : Inapplicable
Deal Type : Inapplicable
Dropless vs. Standard Drops Contralateral Eye Study
Details : Triamcinolone Acetonide is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cataract.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 04, 2015
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
Regulatory Info : Allowed
Registration Country : Switzerland
Brand Name : Pred Forte
Dosage Form : Eye Drop Suspension
Dosage Strength : 0.01
Packaging :
Approval Date : 04/11/1968
Application Number : 34057
Regulatory Info : Allowed
Registration Country : Switzerland
Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Pred Forte
Dosage Form : Eye Drop Suspension
Dosage Strength : 10MG
Packaging :
Approval Date : 01-03-1999
Application Number : 62038
Regulatory Info : Authorized
Registration Country : Spain
Regulatory Info : Marketed
Registration Country : Norway
Prednisolonacetat; Lidokainhydrokloridmonohydrat
Brand Name : Ekyflogyl Vet
Dosage Form : Gel
Dosage Strength : 1.8mg/ml; 8.7mg/ml
Packaging :
Approval Date :
Application Number :
Regulatory Info : Marketed
Registration Country : Norway
Regulatory Info : Marketed
Registration Country : Norway
Mikonazolnitrat; Prednisolonacetat; Polymyksin B sulfat
Brand Name : Otisur
Dosage Form : Ear Drops Suspension
Dosage Strength : 23mg/ml; 5mg/ml; 5500IE/ml
Packaging :
Approval Date :
Application Number :
Regulatory Info : Marketed
Registration Country : Norway
Regulatory Info : Marketed
Registration Country : Norway
Mikonazolnitrat; Prednisolonacetat; Polymyksin B sulfat
Brand Name : Otisur
Dosage Form : Ear Drops Suspension
Dosage Strength : 23mg/ml; 5mg/ml; 5500IE/ml
Packaging :
Approval Date :
Application Number :
Regulatory Info : Marketed
Registration Country : Norway
Regulatory Info : Prescription
Registration Country : Denmark
Miconazole Nitrate; Polymyxin B Sulfate; Prednisolon Acetate
Brand Name : Otisur
Dosage Form : Ear Drops
Dosage Strength : 23mg/ml; 5mg/ml; 5500IU/ml
Packaging :
Approval Date : 07-02-2023
Application Number : 28106592421
Regulatory Info : Prescription
Registration Country : Denmark
Regulatory Info : Prescription
Registration Country : Denmark
Miconazole Nitrate; Polymyxin B Sulfate; Prednisolon Acetate
Brand Name : Surolan Vet.
Dosage Form : Ear Drops
Dosage Strength : 5mg/ml; 23mg/ml; 0.529mg/ml
Packaging :
Approval Date : 27-08-1981
Application Number : 28101035379
Regulatory Info : Prescription
Registration Country : Denmark
Regulatory Info : Allowed
Registration Country : Switzerland
Clotrimazole; Hexamidine Diisetiones; Prednisolone Acetate
Brand Name : Imacort
Dosage Form : Cream
Dosage Strength :
Packaging :
Approval Date : 13/03/1984
Application Number : 45860
Regulatory Info : Allowed
Registration Country : Switzerland
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Prednisolon Mibe
Dosage Form : Eye Drop
Dosage Strength : 10mg/ml
Packaging :
Approval Date : 05-06-2014
Application Number : 2.01E+13
Regulatory Info : Approved
Registration Country : Sweden
Regulatory Info : Deregistered
Registration Country : Sweden
Brand Name : Ultracortenol
Dosage Form : Eye Drop
Dosage Strength : 5mg/ml
Packaging :
Approval Date : 18-10-1966
Application Number : 1.97E+13
Regulatory Info : Deregistered
Registration Country : Sweden
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - SUSPENSION;OPHTHALMIC - 0.2%;10%
USFDA APPLICATION NUMBER - 12813
DOSAGE - SUSPENSION/DROPS;OPHTHALMIC - 1%
USFDA APPLICATION NUMBER - 17011
DOSAGE - SUSPENSION/DROPS;OPHTHALMIC - 0.12%
USFDA APPLICATION NUMBER - 17100
DOSAGE - SUSPENSION/DROPS;OPHTHALMIC - 1%
USFDA APPLICATION NUMBER - 17469
DOSAGE - SUSPENSION/DROPS;OPHTHALMIC - EQ 0.3...DOSAGE - SUSPENSION/DROPS;OPHTHALMIC - EQ 0.3% BASE;1%
USFDA APPLICATION NUMBER - 50586
DOSAGE - OINTMENT;OPHTHALMIC - EQ 0.3% BASE;0...DOSAGE - OINTMENT;OPHTHALMIC - EQ 0.3% BASE;0.6%
USFDA APPLICATION NUMBER - 50612
Related Excipient Companies
EUROAPI
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharm-RX Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kirsch Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Dr. Paul Lohmann GmbH & Co. KGaA
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ACG Worldwide
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Bioplus Life Sciences
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CD Formulation
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gloria Interchem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lonza Capsugel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Bold Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qianhao Chemical (Hebei) Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qualicaps
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Coating Systems & Additives
Parenteral
Solubilizers
Controlled & Modified Release
Topical
Film Formers & Plasticizers
Thickeners and Stabilizers
API Stability Enhancers
Emulsifying Agents
Fillers, Diluents & Binders
Empty Capsules
Taste Masking
Vegetarian Capsules
Surfactant & Foaming Agents
Direct Compression
Granulation
Rheology Modifiers
Lubricants & Glidants
Co-Processed Excipients
Disintegrants & Superdisintegrants
Coloring Agents
Chewable & Orodispersible Aids
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
29
PharmaCompass offers a list of Prednisolone Acetate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Prednisolone Acetate manufacturer or Prednisolone Acetate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Prednisolone Acetate manufacturer or Prednisolone Acetate supplier.
PharmaCompass also assists you with knowing the Prednisolone Acetate API Price utilized in the formulation of products. Prednisolone Acetate API Price is not always fixed or binding as the Prednisolone Acetate Price is obtained through a variety of data sources. The Prednisolone Acetate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A CAS-52-21-1 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of CAS-52-21-1, including repackagers and relabelers. The FDA regulates CAS-52-21-1 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. CAS-52-21-1 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of CAS-52-21-1 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A CAS-52-21-1 supplier is an individual or a company that provides CAS-52-21-1 active pharmaceutical ingredient (API) or CAS-52-21-1 finished formulations upon request. The CAS-52-21-1 suppliers may include CAS-52-21-1 API manufacturers, exporters, distributors and traders.
click here to find a list of CAS-52-21-1 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A CAS-52-21-1 DMF (Drug Master File) is a document detailing the whole manufacturing process of CAS-52-21-1 active pharmaceutical ingredient (API) in detail. Different forms of CAS-52-21-1 DMFs exist exist since differing nations have different regulations, such as CAS-52-21-1 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A CAS-52-21-1 DMF submitted to regulatory agencies in the US is known as a USDMF. CAS-52-21-1 USDMF includes data on CAS-52-21-1's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The CAS-52-21-1 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of CAS-52-21-1 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The CAS-52-21-1 Drug Master File in Japan (CAS-52-21-1 JDMF) empowers CAS-52-21-1 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the CAS-52-21-1 JDMF during the approval evaluation for pharmaceutical products. At the time of CAS-52-21-1 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of CAS-52-21-1 suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a CAS-52-21-1 Drug Master File in Korea (CAS-52-21-1 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of CAS-52-21-1. The MFDS reviews the CAS-52-21-1 KDMF as part of the drug registration process and uses the information provided in the CAS-52-21-1 KDMF to evaluate the safety and efficacy of the drug.
After submitting a CAS-52-21-1 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their CAS-52-21-1 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of CAS-52-21-1 suppliers with KDMF on PharmaCompass.
A CAS-52-21-1 CEP of the European Pharmacopoeia monograph is often referred to as a CAS-52-21-1 Certificate of Suitability (COS). The purpose of a CAS-52-21-1 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of CAS-52-21-1 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of CAS-52-21-1 to their clients by showing that a CAS-52-21-1 CEP has been issued for it. The manufacturer submits a CAS-52-21-1 CEP (COS) as part of the market authorization procedure, and it takes on the role of a CAS-52-21-1 CEP holder for the record. Additionally, the data presented in the CAS-52-21-1 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the CAS-52-21-1 DMF.
A CAS-52-21-1 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. CAS-52-21-1 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of CAS-52-21-1 suppliers with CEP (COS) on PharmaCompass.
A CAS-52-21-1 written confirmation (CAS-52-21-1 WC) is an official document issued by a regulatory agency to a CAS-52-21-1 manufacturer, verifying that the manufacturing facility of a CAS-52-21-1 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting CAS-52-21-1 APIs or CAS-52-21-1 finished pharmaceutical products to another nation, regulatory agencies frequently require a CAS-52-21-1 WC (written confirmation) as part of the regulatory process.
click here to find a list of CAS-52-21-1 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing CAS-52-21-1 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for CAS-52-21-1 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture CAS-52-21-1 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain CAS-52-21-1 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a CAS-52-21-1 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of CAS-52-21-1 suppliers with NDC on PharmaCompass.
CAS-52-21-1 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of CAS-52-21-1 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right CAS-52-21-1 GMP manufacturer or CAS-52-21-1 GMP API supplier for your needs.
A CAS-52-21-1 CoA (Certificate of Analysis) is a formal document that attests to CAS-52-21-1's compliance with CAS-52-21-1 specifications and serves as a tool for batch-level quality control.
CAS-52-21-1 CoA mostly includes findings from lab analyses of a specific batch. For each CAS-52-21-1 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
CAS-52-21-1 may be tested according to a variety of international standards, such as European Pharmacopoeia (CAS-52-21-1 EP), CAS-52-21-1 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (CAS-52-21-1 USP).
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
